China Medical System wins NMPA green light for Phase I study of complement factor B inhibitor CMS-D017

SGX Filings

Feb 03

China Medical System Holdings Limited announced that on Feb, 03 2026 the National Medical Products Administration approved its application to conduct clinical trials in healthy participants for CMS-D017, a self-developed oral selective inhibitor of complement factor B.

The upcoming Phase I trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D017, which is intended for the treatment of complement-mediated kidney diseases such as IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis and C3 glomerulopathy.

CMS-D017 already received NMPA clearance on Jan, 30 2026 for clinical testing in paroxysmal nocturnal hemoglobinuria, and the company plans to explore additional indications including age-related macular degeneration and myasthenia gravis.

According to the company, a future marketing approval for CMS-D017 would complement its nephrology portfolio, which includes the marketed phosphate binder Velphoro and the investigational anemia therapy Desidustat Tablets.

China Medical System said it is preparing to start the clinical study and will update shareholders on further developments, while advising investors to act cautiously when trading its securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121643347"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121643347\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121643347?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121643347","market":"sg","top_or_hot":-1,"title":"China Medical System wins NMPA green light for Phase I study of complement factor B inhibitor CMS-D017","media":"SGX Filings","content":"<p>China Medical System Holdings Limited announced that on Feb, 03 2026 the National Medical Products Administration approved its application to conduct clinical trials in healthy participants for CMS-D017, a self-developed oral selective inhibitor of complement factor B.</p>\n<p>The upcoming Phase I trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D017, which is intended for the treatment of complement-mediated kidney diseases such as IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis and C3 glomerulopathy.</p>\n<p>CMS-D017 already received NMPA clearance on Jan, 30 2026 for clinical testing in paroxysmal nocturnal hemoglobinuria, and the company plans to explore additional indications including age-related macular degeneration and myasthenia gravis.</p>\n<p>According to the company, a future marketing approval for CMS-D017 would complement its nephrology portfolio, which includes the marketed phosphate binder Velphoro and the investigational anemia therapy Desidustat Tablets.</p>\n<p>China Medical System said it is preparing to start the clinical study and will update shareholders on further developments, while advising investors to act cautiously when trading its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Medical System wins NMPA green light for Phase I study of complement factor B inhibitor CMS-D017</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Medical System wins NMPA green light for Phase I study of complement factor B inhibitor CMS-D017\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2026-02-03 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Medical System Holdings Limited announced that on Feb, 03 2026 the National Medical Products Administration approved its application to conduct clinical trials in healthy participants for CMS-D017, a self-developed oral selective inhibitor of complement factor B.</p>\n<p>The upcoming Phase I trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D017, which is intended for the treatment of complement-mediated kidney diseases such as IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis and C3 glomerulopathy.</p>\n<p>CMS-D017 already received NMPA clearance on Jan, 30 2026 for clinical testing in paroxysmal nocturnal hemoglobinuria, and the company plans to explore additional indications including age-related macular degeneration and myasthenia gravis.</p>\n<p>According to the company, a future marketing approval for CMS-D017 would complement its nephrology portfolio, which includes the marketed phosphate binder Velphoro and the investigational anemia therapy Desidustat Tablets.</p>\n<p>China Medical System said it is preparing to start the clinical study and will update shareholders on further developments, while advising investors to act cautiously when trading its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"8A8.SI","symbol_name":"康哲药业控股有限公司","start_time":0,"source_url":"","article_id":"1121643347","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121643347","pubTimestamp":1770127790,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"China Medical System Holdings Limited announced that on Feb, 03 2026 the National Medical Products Administration approved its application to conduct clinical trials in healthy participants for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"8A8.SI":"康哲药业控股有限公司"},"translate_title":"康哲药业补体因子B抑制剂CMS-D017 I期研究获NMPA绿灯","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"8A8.SI":1},"content_text":"China Medical System Holdings Limited announced that on Feb, 03 2026 the National Medical Products Administration approved its application to conduct clinical trials in healthy participants for CMS-D017, a self-developed oral selective inhibitor of complement factor B.\nThe upcoming Phase I trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D017, which is intended for the treatment of complement-mediated kidney diseases such as IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis and C3 glomerulopathy.\nCMS-D017 already received NMPA clearance on Jan, 30 2026 for clinical testing in paroxysmal nocturnal hemoglobinuria, and the company plans to explore additional indications including age-related macular degeneration and myasthenia gravis.\nAccording to the company, a future marketing approval for CMS-D017 would complement its nephrology portfolio, which includes the marketed phosphate binder Velphoro and the investigational anemia therapy Desidustat Tablets.\nChina Medical System said it is preparing to start the clinical study and will update shareholders on further developments, while advising investors to act cautiously when trading its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}